| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |
|
|
|
|||||||
|
|||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
From the Centre d’Investigation Clinique (Y.A., C.B., A.M.B., V.C., M.G., J.L.H., L.M., D.M., W.M.M.S., M.L.W.), Fédération de Neurologie and National Institute of Health and Medical Research (INSERM) Unit 679, Service de Neuroradiologie (D.D.), Service des Explorations Fonctionnelles Neurologiques (B.P.), Service de Neurochirurgie (P.C., S.N.), Groupe Hospitalier Pitié-Salpêtrière, Paris, France; Department of Biostatistics and Medical Information (S.T.d.M.,), Pitié-Salpêtrière Medical University, Paris, France; Centre Hospitalier (J.L.H.), Poitiers, France; and Centre Hospitalier (D.M.), Rouen, France.
* To whom correspondence should be addressed. E-mail: secretaires.cic{at}psl.ap-hop-paris.fr.
Abstract-- Background: Stimulation of the subthalamic nucleus is an effective treatment for advanced Parkinson disease (PD) and is currently performed after a mean disease duration of 14 years, when severe motor complications have resulted in marked loss of quality of life. We examined whether surgery at an early stage would maintain quality of life as well as improve motor function. Methods: Twenty patients with PD of short duration (time elapsed since first symptom ± SD: 6.8 ± 1.0 years) with mild to moderate motor signs (Unified Parkinson’s Disease Rating Scale III "off" medication: 29 ± 12) who responded well to levodopa treatment were included in pairs, matched for age, duration and severity of disease, and impairment in socioprofessional functioning. Patients were prospectively randomized to undergo bilateral subthalamic nucleus stimulation (n = 10) or receive optimized medical treatment (n = 10). Parkinsonian motor scores, quality of life, cognition, and psychiatric morbidity were assessed at inclusion and at 6, 12, and 18 months after randomization. Results: Quality of life was improved by 24% in surgical and 0% in nonsurgical patients (p < 0.05). After 18 months, the severity of parkinsonian motor signs "off" medication, levodopa-induced motor complications, and daily levodopa dose were reduced by 69%, 83%, and 57% in operated patients and increased by 29%, 15%, and 12% in the group with medical treatment only (p < 0.001). Adverse events were mild or transient, and overall psychiatric morbidity and anxiety improved in the surgical group. Conclusions: Subthalamic nucleus stimulation should be considered a therapeutic option early in the course of Parkinson disease.
This article has been cited by other articles:
|
|
 |
|
  S.J. Groiss, L. Wojtecki, M. Sudmeyer, and A. Schnitzler Review: Deep brain stimulation in Parkinson's disease Therapeutic Advances in Neurological Disorders, November 1, 2009; 2(6): 379 - 391. [Abstract] [PDF]
|
|
|
|
 |
|
 C. C. M. Poon and M. G. Irwin Anaesthesia for deep brain stimulation and in patients with implanted neurostimulator devices Br. J. Anaesth., August 1, 2009; 103(2): 152 - 165. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. Poewe Treatments for Parkinson disease--past achievements and current clinical needs Neurology, February 17, 2009; 72(7_Supplement_2): S65 - S73. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. L. Alberts, C. Voelcker-Rehage, K. Hallahan, M. Vitek, R. Bamzai, and J. L. Vitek Bilateral subthalamic stimulation impairs cognitive-motor performance in Parkinson's disease patients Brain, December 1, 2008; 131(12): 3348 - 3360. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. J. Beukers, M. Weisfelt, R. M.A. de Bie, Y. Agid, W.M.M. Schupbach, D. Maltete, and J.L. Houeto NEUROSURGERY AT AN EARLIER STAGE OF PARKINSON DISEASE Neurology, August 21, 2007; 69(8): 811 - 812. [Full Text] [PDF]
|
|
|
|
|
|
D. Riley and A. Lozano The fourth dimension of stereotaxis: Timing of neurosurgery for Parkinson disease Neurology, January 23, 2007; 68(4): 252 - 253. [Full Text] [PDF]
|
|
Read all Correspondence
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |
